Weight-Loss Drugs: Why This Time It May Be a Different Story | 2022 PBMI Annual National Conference

September 14, 2022

The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile, said presented at the annual Pharmacy Benefit Management Institute meeting.

PBMs Can Help Payers Manage Financial Risk for High-Cost Drugs | 2022 PBMI Annual National Conference

September 14, 2022

Timothy Mizak and Nicole Bulochnik of Abarca talked about how can PBMs help payers manage costs through a hybrid network model that leverages value-based and other innovative drug contracts at the Pharmacy Benefit Management Institute (PBMI) annual meeting in Orlando.

A Real-Time Benefit Check Success Story | 2022 PBMI Annual National Conference

September 13, 2022

Executives at Arrive Health and OptumRx say they have ironed out many of the problems with real-time benefit checks, which delivers out-of-pocket cost and prior approval information at the time a prescription is being written.

Nicole Bulochnik of Abarca Health Talks Alternative Cost Management at PBMI

September 13, 2022

Nicole Bulochnik, Vice President of Drug Pricing and Network Strategy at Abarca Health delivers her presentation, "PBM-Payer Partnerships: Insight into Alternative Cost Management Strategies Across Common PBM Levels," during this year's PBMI National Annual Conference in Orlando, FL.

Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting

September 13, 2022

Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.

Defining Value in Healthcare

September 13, 2022

Greg Warren, partner and consulting actuary at Axene Health Partners, discussed the many solutions that have been put forth to address the prescription drug challenges that could bring value to healthcare.

Cate Lockhart Presents on the Uptake of Biosimilars at PBMI 2022

September 13, 2022

Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.